143 related articles for article (PubMed ID: 33683412)
1. The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser CD; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Raggi D; Aurilio G; Casadei C; Hentrich M; Tran B; Dieckmann KP; Brito M; Ruf C; Mazzocca A; Vincenzi B; Stahl O; Bokemeyer C; Oing C
World J Urol; 2021 Sep; 39(9):3407-3414. PubMed ID: 33683412
[TBL] [Abstract][Full Text] [Related]
2. Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser C; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Aurilio G; Casadei C; Tran B; Dieckmann KP; Brito M; Ruf C; Oing C; Bokemeyer C
Eur J Cancer; 2020 Jun; 132():127-135. PubMed ID: 32361383
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of LDH levels in patients with relapsed/refractory seminoma.
Powles T; Bascoul-Mollevi C; Kramar A; Lorch A; Beyer J
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1311-6. PubMed ID: 23640062
[TBL] [Abstract][Full Text] [Related]
5. Testicular seminoma with human chorionic gonadotropin production.
Hori K; Uematsu K; Yasoshima H; Yamada A; Sakurai K; Ohya M
Pathol Int; 1997 Sep; 47(9):592-9. PubMed ID: 9311009
[TBL] [Abstract][Full Text] [Related]
6. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
Beyer J; Collette L; Sauvé N; Daugaard G; Feldman DR; Tandstad T; Tryakin A; Stahl O; Gonzalez-Billalabeitia E; De Giorgi U; Culine S; de Wit R; Hansen AR; Bebek M; Terbuch A; Albany C; Hentrich M; Gietema JA; Negaard H; Huddart RA; Lorch A; Cafferty FH; Heng DYC; Sweeney CJ; Winquist E; Chovanec M; Fankhauser C; Stark D; Grimison P; Necchi A; Tran B; Heidenreich A; Shamash J; Sternberg CN; Vaughn DJ; Duran I; Bokemeyer C; Patrikidou A; Cathomas R; Assele S; Gillessen S;
J Clin Oncol; 2021 May; 39(14):1553-1562. PubMed ID: 33729863
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.
Fosså SD; Oliver RT; Stenning SP; Horwich A; Wilkinson P; Read G; Mead GM; Roberts JT; Rustin G; Cullen MH; Kaye SB; Harland SJ; Cook P
Eur J Cancer; 1997 Aug; 33(9):1380-7. PubMed ID: 9337678
[TBL] [Abstract][Full Text] [Related]
8. The search for biomarkers of metastatic seminoma.
Ruf CG; Khalili-Harbi N; Sachs S; Isbarn H; Wagner W; Matthies C; Meineke V; Fisch M; Chun FK; Abend M
J Urol; 2013 Sep; 190(3):1046-51. PubMed ID: 23583226
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors.
Fedyanin M; Tryakin A; Bulanov A; Vybarava A; Tjulandina A; Chekini D; Sekhina O; Figurin K; Garin A; Tjulandin S
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1259-64. PubMed ID: 25586890
[TBL] [Abstract][Full Text] [Related]
10. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis.
Ahmed KA; Wilder RB
Cancer Epidemiol; 2014 Apr; 38(2):124-8. PubMed ID: 24613492
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.
Stokes W; Amini A; Maroni PD; Kessler ER; Stokes C; Cost CR; Greffe BS; Garrington TP; Liu AK; Cost NG
J Pediatr Urol; 2017 Aug; 13(4):386.e1-386.e7. PubMed ID: 28153774
[TBL] [Abstract][Full Text] [Related]
13. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone.
Patterson H; Norman AR; Mitra SS; Nicholls J; Fisher C; Dearnaley DP; Horwich A; Mason MD; Huddart RA
Radiother Oncol; 2001 Apr; 59(1):5-11. PubMed ID: 11295200
[TBL] [Abstract][Full Text] [Related]
14. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma.
Fosså A; Fosså SD
Br J Urol; 1989 Apr; 63(4):408-15. PubMed ID: 2653557
[TBL] [Abstract][Full Text] [Related]
15. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort.
Soper MS; Hastings JR; Cosmatos HA; Slezak JM; Wang R; Lodin K
Am J Clin Oncol; 2014 Aug; 37(4):356-9. PubMed ID: 23275274
[TBL] [Abstract][Full Text] [Related]
16. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy.
Kobayashi K; Saito T; Kitamura Y; Nobushita T; Kawasaki T; Hara N; Takahashi K
Diagn Pathol; 2013 Apr; 8():57. PubMed ID: 23566361
[TBL] [Abstract][Full Text] [Related]
18. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.
Chung P; Daugaard G; Tyldesley S; Atenafu EG; Panzarella T; Kollmannsberger C; Warde P
Cancer Med; 2015 Jan; 4(1):155-60. PubMed ID: 25236854
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
